alexa Abstract | Role of Prophylactic Octreotide in Pancreaticoduodenectomy: A Single Centre Comparative Study in 456 Whipple's Patients

JOP. Journal of the Pancreas
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Introduction Prophylactic octreotide is controversial in pancreatic surgery in prevention of complications and severity of post-operative pancreatic fistula. We aimed to investigate the influence of prophylactic Octreotide in patients undergoing Pancreaticoduodenectomy and evaluate the cost effectiveness. Methods Prospectively collected data from patients undergoing pancreaticoduodenectomy resections from 2003-2013 (n=456) who had prophylactic subcutaneous administration of octreotide (octreotide group n=255) were compared to patients having pancreaticoduodenectomy where octreotide was not used (no octreotide group n=201). Results Patient groups were well matched with regards to age (p=0.85), sex (p=0.395), and pathology (p=0.79). No octreotide group was associated with reduced hospital stay [octreotide group 20.3 vs. no octreotide group 17.9 days, p<0.001], lower postoperative morbidity [octreotide group n=131(51.4%) vs. no octreotide group n=59(29.3%), p<0.001], and lower significant complications (Clavien Grade II-V), [octreotide group n=94(36%) vs. no octreotide group n=31(15%), p<0.001]. The octreotide group was also associated with significantly higher rate of overall post-operative pancreatic fistula (ISGPF A-C) and serious fistulae (ISGPF B&C) [octreotide group n=75(29.4%) vs. no octreotide group n=42(20.9%), p<0.001] and [octreotide group n=68(27%) vs. no octreotide group n=21(10.4%), p=0.001] respectively. Patients receiving Octreotide were £2370 more expensive to treat. Conclusion Prophylactic octreotide has no role in preventing post-operative pancreatic fistula following Pancreaticoduodenectomy and is associated with increased overall morbidity more severe fistula formation, longer hospital stay & cost of hospitalisation.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Sanjeev Rohatgi Shafiq Rehman Jeremy French Derek Manas Gourab Sen Steven White Bryon Jaques


Octreotide, Pancreas, Pancreas

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version